TNXP
Tonix Pharmaceuticals Exceeds Expectations in Q2 2026 with Strong Execution and Growth
Tonix Pharmaceuticals has reported strong financial results and operational highlights for the second quarter of 2026, exceeding expectations in its commercial business and advancing development pipeline. According to Dr. Seth Lederman, Chief Executive Officer, the company is focused on improving care for patients with debilitating conditions or preventing illness before